Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company’s early cancer detection technology, its place in the the medical imaging market, intellectual property protections, and more.
Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent
December 7, 2023
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited